ESMO 2025: Advancements to improve patient outcomes and quality of life in Immunotherapy

Managing immune toxicities in cancer immunotherapy requires early detection, patient education, and prompt treatment with corticosteroids and immunosuppressants. Chronic side effects can persist long after treatment, underscoring the need for ongoing monitoring. Christina H. Ruhlmann, MD, PhD, Associate Professor at Odense University Hospital, shared these insights and emphasized advancements at ESMO 2025 to improve patient outcomes and quality of life.